Growing patients’ cells in the lab into structures that maintain the characteristics of the patient can help speed drug discovery and tailor treatments.
The quick uptake of tailored therapies by stakeholders in Europe offers the opportunity to propel the Continent ahead of the US to reap commercial success, believes Jurgi Camblong.
